Cancer stem cells (CSCs) are a subpopulation of tumor cells with self-renewal and differentiation capabilities, implicated in tumor initiation, metastasis, and therapeutic resistance. Mitochondria, the powerhouses of cells, play a crucial role in regulating stem cell fate and function. Dysfunctional mitochondria are frequently observed in CSCs, contributing to their aggressive phenotype. Manipulating these altered mitochondrial processes presents a novel avenue for cancer therapy.
The interplay between mitochondrial activity and stem cell behavior offers a unique therapeutic window. By selectively disrupting mitochondrial function in CSCs, the goal is to inhibit their self-renewal capacity and induce differentiation, ultimately limiting tumor growth and preventing recurrence. This approach may prove more effective than traditional therapies that target bulk tumor cells but often leave CSCs untouched. Research in this area holds significant promise for developing new treatments against aggressive and resistant cancers.